TY - JOUR
T1 - Interactions of multiple gene alterations in colorectal liver metastases
AU - Kawaguchi, Yoshikuni
AU - Velasco, Jenilette D.
AU - Arvide, Elsa M.
AU - Wei, Steven H.
AU - Vauthey, Jean Nicolas
N1 - Funding Information:
The authors thank Ms. Ruth Haynes for administrative support in the preparation of this manuscript. Funding: This article was supported in part by the National Institutes of Health (T32 CA 009599) and the MD Anderson Cancer Center Support Grant (CA016672).
Publisher Copyright:
© Chinese Clinical Oncology. All rights reserved.
PY - 2019
Y1 - 2019
N2 - The advancements in next generation sequencing have expanded the information available in clinical practice. Alterations of TP53, APC, RAS, PIK3CA, and SMAD4 are present in more than 10% of patients with colorectal liver metastases (CLM). Of these genes, TP53, RAS and SMAD4 were associated with worse survival in patients undergoing CLM resection. Testing multiple gene alterations provides a more precise prognosis for patients undergoing CLM resection and may be useful for better clinical decision making.
AB - The advancements in next generation sequencing have expanded the information available in clinical practice. Alterations of TP53, APC, RAS, PIK3CA, and SMAD4 are present in more than 10% of patients with colorectal liver metastases (CLM). Of these genes, TP53, RAS and SMAD4 were associated with worse survival in patients undergoing CLM resection. Testing multiple gene alterations provides a more precise prognosis for patients undergoing CLM resection and may be useful for better clinical decision making.
KW - Colorectal liver metastasis (CLM)
KW - Liver resection
KW - Somatic gene alteration
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85073124310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073124310&partnerID=8YFLogxK
U2 - 10.21037/cco.2019.08.06
DO - 10.21037/cco.2019.08.06
M3 - Review article
C2 - 31500427
AN - SCOPUS:85073124310
SN - 2304-3865
VL - 8
JO - Chinese clinical oncology
JF - Chinese clinical oncology
IS - 5
M1 - 50
ER -